![Andrew Nebel](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Andrew Nebel is currently the Chairman at Duchenne UK.
He previously worked as the Director of Marketing and Communications at Barnardo's.
Aktive Positionen von Andrew Nebel
Unternehmen | Position | Beginn |
---|---|---|
Duchenne UK
![]() Duchenne UK Investment Trusts/Mutual FundsMiscellaneous Duchenne UK is a UK-based charity that focuses on finding effective treatments for Duchenne muscular dystrophy (DMD), a progressive condition that weakens all the muscles in the body and is diagnosed in childhood. Additionally, Duchenne connects and supports families affected by DMD. The charity funds research that aims to provide treatments for those affected by DMD and removes roadblocks that prevent patients from accessing the treatments they need. The British company was founded in 2012 by Nick Crossley, Emily Crossley, and Alex Johnson, and Emily Crossley and Alex Johnson have been the CEOs since 2012. | Vorsitzender | - |
Ehemalige bekannte Positionen von Andrew Nebel
Unternehmen | Position | Ende |
---|---|---|
Barnardo's
![]() Barnardo's Miscellaneous Commercial ServicesCommercial Services Barnardo's provides charitable services. The company was founded by Thomas John Barnardo in 1845 and is headquartered in Ilford, the United Kingdom. | Public Communications Contact | 01.07.2008 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Barnardo's
![]() Barnardo's Miscellaneous Commercial ServicesCommercial Services Barnardo's provides charitable services. The company was founded by Thomas John Barnardo in 1845 and is headquartered in Ilford, the United Kingdom. | Commercial Services |
Duchenne UK
![]() Duchenne UK Investment Trusts/Mutual FundsMiscellaneous Duchenne UK is a UK-based charity that focuses on finding effective treatments for Duchenne muscular dystrophy (DMD), a progressive condition that weakens all the muscles in the body and is diagnosed in childhood. Additionally, Duchenne connects and supports families affected by DMD. The charity funds research that aims to provide treatments for those affected by DMD and removes roadblocks that prevent patients from accessing the treatments they need. The British company was founded in 2012 by Nick Crossley, Emily Crossley, and Alex Johnson, and Emily Crossley and Alex Johnson have been the CEOs since 2012. | Miscellaneous |